Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · Real-Time Price · USD
6.66
+0.16 (2.46%)
Oct 29, 2024, 4:00 PM EDT - Market closed
Biodexa Pharmaceuticals Stock Forecast
BDRX's stock price has decreased by -93.04% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for BDRX stock has a target of 200, which predicts an increase of 2,903.00% from the current stock price of 6.66.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 8, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for BDRX is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 |
|---|---|---|
| Strong Buy | 1 | 1 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Total | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Initiates $200 | Strong Buy | Initiates | $200 | +2,903.00% | Feb 8, 2024 |
Financial Forecast
Revenue This Year
33.96K
from 381.00K
Decreased by -91.09%
Revenue Next Year
16.98K
from 33.96K
Decreased by -49.98%
EPS This Year
-0.16
from -224.13
EPS Next Year
-0.10
from -0.16
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 34,955 | 17,483 | 8,064 | |
| Avg | 33,956 | 16,983 | 7,834 | |
| Low | 32,624 | 16,317 | 7,526 |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -90.8% | -48.5% | -52.5% | |
| Avg | -91.1% | -50.0% | -53.9% | |
| Low | -91.4% | -51.9% | -55.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -0.16 | -0.11 | -0.12 | |
| Avg | -0.16 | -0.10 | -0.12 | |
| Low | -0.15 | -0.10 | -0.11 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.